Correction: Development of ACE2 autoantibodies after SARS-CoV-2 infection.

Correction: Development of ACE2 autoantibodies after SARS-CoV-2 infection.

[This corrects the article DOI: 10.1371/journal.pone.0257016.].

Saved in:

Bibliographic Details
Main Authors:	John M Arthur, J Craig Forrest, Karl W Boehme, Joshua L Kennedy, Shana Owens, Christian Herzog, Juan Liu, Terry O Harville
Format:	Article
Language:	English
Published:	Public Library of Science (PLoS) 2024-01-01
Series:	PLoS ONE
Online Access:	https://doi.org/10.1371/journal.pone.0314426
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Sequential SARS-CoV-2 mRNA Vaccination Induces Anti-Idiotype (Anti-ACE2) Antibodies in K18 Human ACE2 Transgenic Mice
by: Craig P. Collins, et al.
Published: (2025-02-01)

Autoantibodies and SARS-CoV-2 infection: A case report
by: T. I. Kalenchic, et al.
Published: (2022-07-01)

Human soluble ACE2 improves the effect of remdesivir in SARS‐CoV‐2 infection
by: Vanessa Monteil, et al.
Published: (2020-12-01)

Relationship of ACE1 and ACE2 genetic polymorphisms on SARS-CoV-2 infection and severity of symptoms in different regions of Iraq
by: Bilal Ali Khashan, et al.
Published: (2024-02-01)

Role of ACE1, ACE2, and CCR5-Δ32 Polymorphisms in the Transmission of SARS-CoV-2 to Intimate Contacts
by: Maria Pina Dore, et al.
Published: (2025-05-01)

ACE2 Receptor Usage across Animal Species by SARS-CoV-2 Variants
by: Masato Hatta, et al.
Published: (2025-08-01)

Daphnetin may protect from SARS-CoV-2 infection by reducing ACE2
by: Qian-wen Yang, et al.
Published: (2024-12-01)

ACE2 and TMPRSS2 gene expression is reduced acutely in SARS-CoV-2 patients but returns to normal with recovery
by: Vanessa Hui En Chen, et al.
Published: (2025-04-01)

Evolutionary pathways to SARS-CoV-2 resistance are opened and closed by epistasis acting on ACE2.
by: Gianni M Castiglione, et al.
Published: (2021-12-01)

Clinical grade ACE2 as a universal agent to block SARS‐CoV‐2 variants
by: Vanessa Monteil, et al.
Published: (2022-07-01)

The Renin–Angiotensin System Modulates SARS-CoV-2 Entry via ACE2 Receptor
by: Sophia Gagliardi, et al.
Published: (2025-07-01)

Comparison of transgenic and adenovirus hACE2 mouse models for SARS-CoV-2 infection
by: Raveen Rathnasinghe, et al.
Published: (2020-01-01)

Computational Design and Evaluation of Peptides to Target SARS-CoV-2 Spike–ACE2 Interaction
by: Saja Almabhouh, et al.
Published: (2025-04-01)

Age-dependent ACE2/TMPRSS2 expression and SARS-CoV-2 household transmission in Gran Canaria.
by: Jesús Poch-Páez, et al.
Published: (2025-01-01)

Age-dependent ACE2/TMPRSS2 expression and SARS-CoV-2 household transmission in Gran Canaria
by: Jesús Poch-Páez, et al.
Published: (2025-01-01)

Resistance to SARS-CoV-2 infection in camelid nasal organoids is associated with lack of ACE2 expression
by: Tim I. Breugem, et al.
Published: (2024-09-01)

ACE2 Receptor and Antibody Binding to SARS-CoV‑2 Spikes and Virions by Single-Molecule Fluorescence
by: Souradip Dasgupta, et al.
Published: (2025-07-01)

In vivo production of engineered ACE2 decoy protects lungs from SARS-CoV-2 infection
by: Yuta Suzuki, et al.
Published: (2025-03-01)

The SARS-CoV-2 Spike protein has a broad tropism for mammalian ACE2 proteins.
by: Carina Conceicao, et al.
Published: (2020-12-01)

Antiviral activity of an ACE2-Fc fusion protein against SARS-CoV-2 and its variants.
by: Ernesto Bermúdez-Abreut, et al.
Published: (2025-01-01)

Combined immunization with SARS-CoV-2 spike and SARS-CoV nucleocapsid protects K18-hACE2 mice but increases lung pathology
by: Jaekwan Kim, et al.
Published: (2025-02-01)

Dual inhibition of ACE-2 and TMPRSS2: A promising strategy to mitigate SARS-CoV-2 severity in smokers
by: Kingshuk Panda, et al.
Published: (2025-09-01)

Altered plasma levels of the SARS-CoV-2-related proteins ACE2 and TMPRSS2 in patients with Crohn’s disease
by: Jorge Sáez-Leyva, et al.
Published: (2024-12-01)

Analysis of the docking property of host variants of hACE2 for SARS-CoV-2 in a large cohort.
by: Hyojung Paik, et al.
Published: (2022-07-01)

Human ACE2 transgenic pigs are susceptible to SARS-CoV-2 and develop COVID-19-like disease
by: Long Fung Chau, et al.
Published: (2025-01-01)

Interaction of toll-like receptors and ACE-2 with different variants of SARS-CoV-2: A computational analysis
by: Azadeh Zahmatkesh, et al.
Published: (2024-07-01)

Characterization of key spike RBD residues influencing SARS-CoV-2 variant adaptation to avian ACE2
by: Weitong Yao, et al.
Published: (2025-07-01)

Engineering functionally-optimized aptamers against SARS-Cov-2 for blocking spike-ACE2 interaction and aptasensor detection
by: Xiangdong Lai, et al.
Published: (2025-08-01)

In Vitro Inhibitory Effect of Nigella sativa L. Extracts on SARS-COV-2 Spike Protein-ACE2 Interaction
by: Najma Ali, et al.
Published: (2024-01-01)

Comparative analysis reveals the species-specific genetic determinants of ACE2 required for SARS-CoV-2 entry.
by: Wenlin Ren, et al.
Published: (2021-03-01)

Characterizing neuroinvasion and neuropathology of SARS-CoV-2 by using AC70 human ACE2 transgenic mice
by: Jason C. Hsu, et al.
Published: (2024-09-01)

Critical amino acid residues in human ACE2 for SARS-CoV-2 spike protein binding and virus entry
by: Weiyi Chen, et al.
Published: (2025-08-01)

Human ACE2 expression, a major tropism determinant for SARS-CoV-2, is regulated by upstream and intragenic elements.
by: John N Snouwaert, et al.
Published: (2023-02-01)

In vitro evolution predicts emerging SARS-CoV-2 mutations with high affinity for ACE2 and cross-species binding.
by: Neil Bate, et al.
Published: (2022-07-01)

Immunogenic Potential of Selected Peptides from SARS-CoV-2 Proteins and Their Ability to Block S1/ACE-2 Binding
by: Lara Cristina da Silva Lima, et al.
Published: (2025-01-01)

Engineered ACE2 decoy in dry powder form for inhalation: A novel therapy for SARS-CoV-2 variants
by: Takaaki Ito, et al.
Published: (2025-06-01)

Structural and molecular basis of the epistasis effect in enhanced affinity between SARS-CoV-2 KP.3 and ACE2
by: Leilei Feng, et al.
Published: (2024-11-01)

Receptor binding and structural basis of raccoon dog ACE2 binding to SARS-CoV-2 prototype and its variants.
by: Chunliang Luo, et al.
Published: (2024-12-01)

Newly Proposed Dose of Daclatasvir to Prevent Lethal SARS-CoV-2 Infection in Human Transgenic ACE-2 Mice
by: Mayara Mattos, et al.
Published: (2024-11-01)

Evaluation and Its Impact of SARS-CoV-2 Inactivated Vaccine Candidate in K18-hACE2 Mice
by: Rofiqul A'la, et al.
Published: (2025-04-01)